Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIT Margin: 2019-2023

Historic EBIT Margin for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to -249.42%.

  • ADC Therapeutics' EBIT Margin fell 24534.00% to -249.42% in Q3 2023 from the same period last year, while for Sep 2023 it was -241.08%, marking a year-over-year decrease of 16047.00%. This contributed to the annual value of -58.90% for FY2022, which is 71275.00% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' EBIT Margin is -249.42%, which was down 21.31% from -205.62% recorded in Q2 2023.
  • ADC Therapeutics' EBIT Margin's 5-year high stood at 1,361.82% during Q1 2021, with a 5-year trough of -162,315.79% in Q3 2020.
  • In the last 3 years, ADC Therapeutics' EBIT Margin had a median value of -249.42% in 2023 and averaged -232.33%.
  • In the last 5 years, ADC Therapeutics' EBIT Margin tumbled by 16,231,579bps in 2020 and then skyrocketed by 16,187,621bps in 2021.
  • Over the past 5 years, ADC Therapeutics' EBIT Margin (Quarterly) stood at 0.00% in 2019, then plummeted by 16,231,579bps to -162,315.79% in 2020, then surged by 16,187,621bps to -369.08% in 2021, then spiked by 35,370bps to -15.38% in 2022, then crashed by 24,534bps to -249.42% in 2023.
  • Its EBIT Margin was -249.42% in Q3 2023, compared to -205.62% in Q2 2023 and -271.55% in Q1 2023.